INTRODUCTION
Endogenous peptides with regulatory functions serve as hormones, neuropeptides or neurotransmitters, and cytokines, stimulating interest in their therapeutic use. Moreover, small peptides represent an important nutritional source of amino acids. Membrane transporters such as the proton-coupled oligopeptide transporters, PEPT1 and PEPT2 (SLC15A1 and SLC15A2), facilitate absorption and distribution of small peptides (2-3 residues) and polar peptoid drugs that would otherwise not cross lipid membranes. The intestinal PEPT1 transporter is involved in carrier-mediated uptake of peptide-like drugs such as cephalexin, ACE-inhibitors, and 5'-amino acid esters of the antiviral nucleosides, acyclovir, AZT, and ganciclovir (Ganapathy et al., 1995; Han et al., 1998) . Bioavailablility of the prodrug L-valacyclovir (VAC) is substantially increased by PEPT1 transport activity.
Response to drug therapy varies in-between patients, in part because of genetic differences among individuals. Polymorphisms of drug receptors, metabolizing enzymes, and transporters each can affect therapeutic efficacy (Licinio and Wong, 2002) . While the effect of genetic variants has been well documented for drug metabolizing enzymes, drug transporters have been less thoroughly studied (Dai and Sadee, 2005 ). Yet, recent results demonstrate a pervasive role for genetic variants of several membrane transporters, such as MDR1 (Hoffmeyer et al., 2000) . For the PEPT1 substrate VAC, a significantly larger interindividual than intraindividual variability in intestinal absorption suggests the presence of genetic factors, potentially involving PEPT1 (Phan et al., 2003) . In a previous sequencing study of PEPT1 involving 44 ethnically diverse individuals, 13 SNPs had been located in the coding region of PEPT1 (Zhang et al., 2004) . Functional characterizations of the nine non-synonymous SNPs revealed that only one rare variant had reduced transport activity as a result of reduced protein expression. The UCSF Membrane Transporter Group had also performed a more extensive sequence analysis of PEPT1, of which the results are publicly available (http://pharmacogenetics.ucsf.edu/set1/index.html#SLC15A1).
We had independently prepared mutant PEPT1 plasmids for functional in vitro analysis based on these more extensive sequence data, and have now confirmed and extended the functional JPET #94615 5 analysis of PEPT1 variants. Moreover, we have sequenced not only PEPT1 coding regions but also adjoining intronic regions which may be subject to alternative splicing. The large sample size also permits detailed analysis of haplotype structures and ethnic distributions of the main alleles and haplotypes.
Genomic surveys have revealed that regulatory polymorphisms acting in cis (i.e., on the transcription of the gene they are located in) represent a main source of human phenotypic variability (Rockman and Wray, 2002; Johnson et al., 2005) . Moreover, polymorphisms in transcribed regions of a gene can affect mRNA processing and turnover .
Hoffmeyer et al. (Hoffmeyer et al., 2000) for instance observed that a synonymous SNP in ABCB1 correlates with expression levels and in vivo activity of the protein product of ABCB1. We have now demonstrated that this SNP (C3435T) alters mRNA turnover, because of changes in mRNA folding . Nearly half of all human genes are alternatively spliced (Modrek and Lee, 2002) , which can be subject to genetic variations. Yet a majority of these cisacting polymorphisms has yet to be discovered. We use here a quantitative analysis of each of two PEPT1 alleles in small intestines, the main site of expression, as an integrative measure of all cis-acting polymorphisms affecting gene regulation and mRNA processing, as previously shown for PEPT2 (Pinsonneault et al., 2004) . Any significant differences in allelic ratios between genomic DNA and mRNA (measured as cDNA) reveals the presence of allelic expression imbalance (AEI) (Yan et al., 2002) and hence the presence of cis-acting factors. Moreover, we have measured the relative formation of a splice variant, PEPT1-RF (Urtti et al., 2001) ,previously shown in vitro to regulate H + -dependent PEPT1 transport (Saito et al., 1997) . Taken together, this study provides a quantitative assessment of genetic variability of PEPT1, providing details on a new but rare functional variant in the coding region, while showing that genetic factors overall appear to play only a small role in determining interindividual variability in PEPT1 transporter activity in intestines. 488-conjugated goat anti-rabbit IgG, alexa 488-conjugated phalloidin, and propidium iodide were from Molecular Probes (Eugene, OR, USA). Rabbit-anti-PEPT1, raised against a peptide corresponding to the last 15 carboxy-terminal amino acid residues of the human peptide transporter PEPT1, was used as previously described (Nielsen et al., 2001 ). Other chemicals were either analytical or HPLC grade.
Genotyping and variant construction.
Primers for exons and adjoining intron regions (ca. 50 bp) for PEPT1 (NCBI reference sequence: 
Haplotype analysis
Haplotype were determined using the PHASE algorithm. The method regards the unknown haplotypes as unobserved random quantities and aims to evaluate their conditional distribution in light of the genotype data (Stephens et al., 2001) .
Cell culture and transfection
Monkey Cos7, Chinese hamster ovary cells (CHO), and human embryonic kidney cells (HEK 293) were obtained from American Type Culture Collection. Cos7 cells were grown in DME H16/F-12 medium with NEAA (1:1) containing 10% fetal bovine serum and penicillin (100 units/mL) and streptomycin (100 µ g/mL) at 37 ° C in a humidified atmosphere with 5% CO 2 . CHO cells were grown in F-12 medium with NEAA containing 10 % fetal bovine serum under the same conditions as Cos7 cells. Cos7 and CHO cells were plated in 12-well plates at 3. The tubes were centrifuged at 10 000 g for 10 minutes. The protein content in lysates free of cellular debris was determined by the method of Bradford, using a Bio-Rad protein assay kit according to the manufacturers´ instructions (Bio-Rad, Hemel Hempstead, UK).
High pressure liquid chromatography
The HPLC system used was a Shimadzu HPLC SCL-10A system. Cephalexin was separated by 
Data Analysis
Total uptake of Gly-Sar in transfected HEK 293 cells was corrected for non-cellular uptake using mannitol as previously described (Bravo et al., 2004) and for the uptake of Gly-Sar in mock transfected HEK 293 cells. The cellular carrier-mediated uptake as a function of apical Gly-Sar concentration was fitted to a Michaelis-Menten type equation (Equation 1),
where V = uptake rate (pmol × mg protein
), V max = maximum uptake rate (pmol × mg
JPET #94615
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The IC 50 values were determined from the dose-response inhibition curves. These values were calculated with the SigmaPlot software as described earlier (Covitz et al., 1996) .
Values are given as mean ± SD. The statistical significance of the results was determined using two-tailed paired Students t-test. P < 0.05 was considered significant. * P < 0.05 ** P < 0.01 *** P < 0.001.
Analysis of sequence variations and nucleotide diversity.
The neutral parameter θ , the nucleotide diversity π and the Tajima variable D were calculated as described by (Tajima, 1989) .
The nucleotide diversity π is the average number of pair-wise nucleotide differences between sequences in a sample. It depends on both the number of polymorphic sites and their frequency. used to detect departures from the standard neutral model (Stephens et al., 2001) . A negative D value can be evidence for selection of one specific allele over alternate alleles. If, however, the majority of genes have a negative D it could mean that the human study population underwent a recent expansion (Stephens et al., 2001) .
SNaPshot assay and quantitative analysis of allelic ratios in genomic DNA and mRNA in small intestinal samples 56 biopsies of small intestine were obtained from the Cooperative Human Tissue Network at the Ohio State University. Tissues were obtained from the duodenum, the jejunum, the ileum, or unspecified small intestines. Most tissues were frozen between 15 and 30 minutes post-biopsy, although some had longer intervals (1 -3 hours). Genomic DNA and RNA were extracted from each sample as described (Pinsonneault et al., 2004) . In short, frozen tissue samples were pulverized under liquid nitrogen. The frozen powder was portioned into aliquots for DNA and RNA extractions. DNA was prepared by digestion of the pellet or frozen powder with sodium dodecyl sulfate and proteinase K followed by sodium chloride precipitation of proteins (Miller et al., 1988) .
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The DNA in the supernatant was further purified and recovered by ethanol precipitation. For RNA preparation, the starting material was homogenized in TRIzol ™ reagent (monophasic solution of phenol and guanidine isothiocyanate) (Invitrogen, Carlesbad, CA), and extracted with chloroform.
The RNA was recovered by precipitation with isopropanol followed by centrifugation. For additional purification, the RNA precipitate was dissolved in RNase free water or Qiagen buffer (Qiagen, Valenia, CA), then extracted using Qiagen RNeasy™ columns according to the manufacturers instructions. Complementary DNA (cDNA) was generated from the mRNA by Superscript II reverse transcriptase (Invitrogen) employing oligo-dT and a PEPT1-specific reverse primer (ACACTAGAAGCGTGTGGCGTT).
SNaPshot is a primer extension method we have adapted for analysis on the ABI 3730, with a few modifications needed to accommodate data handling. We selected an abundant marker SNP (synonymous) in the transcribed region of PEPT1 (rs1339067, exon 17 position 78, T1347T). All 56 samples were first genotyped and then 24 heterozygous samples selected for allele-specific mRNA analysis. A stretch of genomic DNA (~70 bp's) or cDNA, generated from mRNA, containing the marker SNP, was amplified by PCR, and the allelic ratio was measured in heterozygous samples by primer extension using fluorescently labeled terminator nucleotides, as previously described for PEPT2 (Pinsonneault et al., 2004) . Genomic DNA serves as an internal 
RT-PCR of PEPT1 splice variant.
cDNA preparations from 32 intestinal samples were also used for analysis of the RF splice variant, which consists of exons 3 -7 (where exons 3 and 7 are partially shared with full-length wildtype PEPT1), and one additional exon 7' further downstream (located between exons 18 and 19) (Urtti et al., 2001) were located in the intronic or non-coding region. In the exonic coding regions, 9 of the detected single nucleotide polymorphism sites were non-synonymous and 8 were synonymous. Five SNPs were located in the transmembrane region, and the remaining 11 SNPs in the extracellular loops, with no SNPs detected in the intracellular loops (cf. Figure 1 ).
For some SNPs ethnic differences in distribution were observed. One non-synonymous (exon 17, SNP#2) and three intronic SNPs (exon 1, SNP#4, exon 15, SNP#1, exon 21, SNP# 1) differed at least twofold between ethnic groups, compared to mean allele frequency (cf. Table 1) .
We analyzed the sequence data to detect any evolutionary trends suggesting selection pressures for genetic variants. (Stephens et al., 2001) . African Americans had the highest neutral parameter value. The neutral parameter for the entire population was greater than that of the individual subpopulation, which is consistent with the existence of population substructure in this sample set.
Haplotype analysis
Using the PHASE algorithm, 107 distinct haplotypes emerged over 10 PHASE runs of which 24
were unambiguous haplotypes (i.e., were derived from homozygotes and single-site heterozygotes). Of these, 17 had a frequency of 1 %, accounting for 82.9 % of all haplotypes JPET #94615 16 (Table 3 ). The two most common haplotypes 1 and 2 were more frequent in Caucasians than African Americans. On the other hand, 10 out of the remaining 15 haplotypes were more frequent in African Americans, showing greater sequence diversity in this population.
Functional characterization of PEPT1 variants
Eight non-synonymous variants were functionally characterized to study the phenotypic influence of genetic variation of the PEPT1 transporter. As a first screen the uptake of cephalexin was (Table 4) . However, uptake studies of Gly-Sar at a low substrate concentration (20µM) revealed functional differences between the variants (Figure 4 ).
At all pH levels, PEPT1-mediated uptake of Gly-Sar was significantly lower for the F28Y variant compared to WT, S117N and G419A (Figure 4 ). For the latter three, the uptake increased as the extracellular pH was lowered from 7.4 to 5. On the other hand, differences between wild-type and F28Y varied with pH with a maximum at pH 5.5 -6.0. The pH dependent Gly-Sar uptake experiments were repeated under identical conditions except for using 5 mM Gly-Sar instead of 20 µ M. Under these high substrate conditions, both WT and the PEPT1 variants all showed similar absolute uptake rates and similar uptake patterns as a function of pH (data not shown).
To explore the transport kinetics further, we investigated the concentration-dependent uptake of (Table 4 ). The K m value for F28Y was significantly higher than the K m value for WT at both pH 5 and 6 with no differences in the V max values.
To study substrate selectivity, competitive inhibition of cephalexin uptake was tested with enalapril maleate, VAC, and Leu-Ala. The IC 50 values of enalapril maleate (2.1 mM), VAC (1.2 mM), and Leu-Ala (0.67 mM) were determined and the uptake of cephalexin measured in the variants at a concentration affording 70 % inhibition of cephalexin in the wild-type transfected cells (Table 5) . No significant differences were observed between any of the variants in terms of cephalexin inhibition, the exception being a VAC inhibition in F28Y cells. However, standard deviations of the assays were relatively high and thus, the sensitivity of this assay is relatively low.
Subcellular expression of WT and F28Y in transiently transfected HEK 293 cells
The subcellular localization of PEPT1 in HEK 293 cells transiently transfected with WT and F28Y is shown in figure 5 . For both WT and F28Y, the PEPT1 protein was primarily localized in the cell membrane and in adjacent vesicles. No staining was observed in mock transfected cells or in preparations without primary antibody (data not shown). Therefore, subcellular localization of the PEPT1 protein in HEK 293 cells appears to be similar for WT and F28Y.
Measurement of allelic expression imbalance on PEPT1 in human small intestines
To detect any cis-acting polymorphisms affecting mRNA levels, we measured allelic ratios in genomic DNA and mRNA of human intestinal samples, using a nonsynonymous marker SNP in exon 17 (T1347T). Of 56 samples genotyped, 24 were heterozygous for T1347T and eligible for allele-specific mRNA analysis using SNaPshot (Figure 6 panel A). Because the assay was unusually precise, at least in part owing to the robust expression of PEPT1 in the small intestinal samples, a majority showed allelic mRNA ratios significantly different from those in genomic DNA, indicating the presence of some cis-acting factor. However, only 7 samples showed deviations from unity of 20% to maximally 30%. This result documents the presence of allelic expression imbalance, but the differences are relatively small. We cannot exclude the possibility that some differences between alleles could have been generated by differential decay after dissection and storage. However, a majority of samples showed differences in allelic mRNA ratios deviating less than 10% for the expected unity (after correction for the genomic DNA ratios). Moreover, we use JPET #94615 18 a gene-specific primer for the cDNA synthesis with close proximity to the marker SNP, so that some mRNA degradation can be accommodated. In each sample, one allele serves as the control for the other, making this analysis more precise than is possible for absolute mRNA measurements.
Measurements of the splice variant PEPT1-RF.
We determined the relative levels of WT PEPT1 and PEPT1-RF mRNA in 32 intestinal samples with the use of real-time RT-PCR, using exon-specific primers. Between 2 and 44% of the total PEPT1-related mRNA was attributable to PEPT1-RF, demonstrating significant variability among individuals (Figure 6 panel B) . We did not attempt to determine the overall amount of PEPT1 mRNA because these samples were collected under varying conditions, so that some degradation is unavoidable. We cannot exclude the possibility that the two splice forms decay differentially after the tissue has been dissected, but the large variations argue against this as a likely explanation of the results.
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DISCUSSION
This study combines a large sequencing analysis of PEPT1 in 247 ethnically diverse subjects, with an experimental approach to assess cis-acting polymorphisms affecting gene regulation and mRNA processing. Allelic diversity and haplotype distributions were determined, and nonsynonymous SNPs evaluated for functional effects, extending an earlier study (Zhang et al., 2004) . Moreover, we determined allelic expression imbalance and alternative splicing to regulatory variants of PEPT1 in human intestinal samples. The results demonstrate a lack of functional genetic defects, with only rare variants affecting protein function or gene regulation.
The significance of variable splicing remains to be determined. This study validates the use of PEPT1 as an entry port for oral bioavailability for peptidomimetic drugs, with genetic variability in intestinal transport activity expected to be limited.
Because we had access to a large sequence database, the results were evaluated in terms of population dynamics and evolution, using the ratio of synonymous over non-synonymous
SNPs as an indicator. This assumes that nonsynonymous substitution may be deleterious and selected against. Nucleotide diversity, π, was consistently lower than θ yielding negative Tajima's D-values similar to those observed previously (Cargill et al., 1999; Halushka et al., 1999; Stephens et al., 2001) , except for Hispanics, possibly due to small sample size. This finding is consistent with selection of one specific allele over alternate alleles. Ratios of π non-synonymous over π synonymous , overall < 1, are similar to those reported earlier (Cargill et al., 1999; Halushka et al., 1999) in studies of genetic variation in over 75 genes. Ratios over 1 indicate that there is a selection for a function of a given gene, which does not seem to be the case for PEPT1.
Overall, our results confirm earlier findings (Zhang et al., 2004) observed in a smaller sample set. Most coding region SNPs were observed in both sample sets (Zhang et al., 2004) , with some exceptions. Most nonsynonymous SNPs occur in poorly conserved regions, and the majority of protein variants tested showed no altered functionality. Only two rare SNPs lead to a functional change: PEPT1-P586L studied earlier (Zhang et al., 2004) and PEPT1-F28Y
characterized here. Whereas P586L shows decreased transport capacity due to reduced protein JPET #94615 20 expression, F28Y has similar expression levels as wild-type but altered affinity (i.e., higher K m value for dipeptide transport).
In addition to coding sequence analysis performed in the earlier study (Zhang et al., 2004) , we analyzed adjoining intronic regions, and a portion of the deduced upstream promoter region. Approximately 6% of the mutations occur in introns and could potentially modulate consensus splice-site signals; such mutations have the potential to cause exon skipping (Aretz et al., 2004) . The highest allele frequency (30 %) was observed for one SNP in the intronic region adjoining exon 13. PEPT1 has 23 exons while the splice variant, PEPT1-RF, has 6. PEPT1-RF shares 3 exons completely and 2 exons partially with PEPT1 (Urtti et al., 2001) . No polymorphisms were observed in regions surrounding the splice sites that would predict genetic differences in PEPT1-RF formation.
In vitro uptake studies in transiently transfected CHO and Cos7 cells were performed for phenotypic characterization of non-synonymous PEPT1 variants. Of 8 variants investigated, one (F28Y) showed significantly reduced cephalexin uptake compared to wild type. Detailed kinetic studies in HEK 293 cells demonstrated that the K m and V max values for Gly-Sar uptake by variants S117N and G419A were similar to values obtained for WT PEPT1. This confirms the earlier study (Zhang et al., 2004) where Gly-Sar uptake was measured in transiently transfected HeLa cells,
showing that S117N, V122M, G419A and T451N had similar Gly-Sar uptake compared to wildtype PEPT1.
For F28Y, altered transport of Gly-Sar and cephalexin was observed in various transfected mammalian cells. PEPT1 transport is partly driven by the proton-gradient across intestinal epithelial cells. The pH-dependence for Gly-Sar transport via WT, S117N, and G419A
reported here is similar to that obtained in oocytes transfected with PEPT1, and in Caco-2 cells where functional NHE3 activity was suppressed with inhibitors (Kennedy et al., 2002) . This indicates that both S117N and G419A retain substrate transport activity with unchanged pH dependence. In contrast, F28Y showed a pH-profile similar to that previously observed in Caco-2 cells with functional NHE3 activity and the presence of the regulatory factor PEPT1-RF (Saito et al., 1997; Kennedy et al., 2002) . Altered pH dependence of F28Y could be related to the JPET #94615 21 phenylalanine to tyrosine substitution, which may affect proton binding to His57, shown to be important for proton binding (Fei et al., 1997; Fei et al., 1998) . Previous studies have shown that tyrosine residues in positions 54, 65, and 167 appear to be involved in proton binding (Yeung et al., 1998; Chen et al., 2000) . For position 282 a substitution of arginine to lysine did not alter PEPT1 transport activity whereas substitution to glutamine resulted in the uncoupling of proton dependence (Kulkarni et al., 2003) . Since the 3D structure of PEPT1 is currently unknown, no one knows how these residues interact. Sequence comparison across different species showed that the surounding F28Y region (Urtti et al., 2001; Zhang et al., 2004 ) is highly conserved across species. The only other PEPT1 variant in a highly conserved region is V21I, showing no functional defect. However, in contrast to Phe28, which was conserved across all species, replacement of valine with isoleucine occurs in gallus (cf. table 6). Lee et al. (Lee et al., 1999) proposed a theoretical model for PEPT1. The model, based on pair-wise calculations and amphipathicity, proposed that TMDs with highest amphipathicity faced a central channel. Using this computational model, they identified amino acids that were likely to alter PEPT1 transport function. Three out of four mutations implicated by this model were indeed defective in Gly-Sar transport. None of the natural PEPT1 variants identified here are in regions proposed to be relevant for transport function, consistent with a lack of functional effect of these natural variants.
Whereas most previous studies on human genetic variability have focused on coding regions, it is likely that more genetic variants affect mRNA levels by multiple mechanisms. Thus, synonymous SNPs, and SNPs in intronic or regulatory regions, could affect PEPT1 expression or splicing, and hence PEPT1 activity. We have addressed this possibility by measuring allelic expression imbalance, with a marker SNP in exon 17 in relevant target tissues, in this case small intestines. We obtained tissue samples from various locations (duodenum, jejunum, ileum), but did not attempt to analyze these separately, because we were limited in sample number. Still, the 24 samples analyzed permit a survey of 48 alleles, sufficient to detect any functional polymorphism with ~5% allele frequency. Only 7 samples displayed allelic mRNA expression imbalance with 20-30% deviations from unity, and indicate the presence of frequent cis-acting polymorphisms with limited effect on relative mRNA levels. One can use allelic mRNA ratios as a JPET #94615 22 phenotype for identifying any polymorphisms in the PEPT1 gene locus (including potential regulatory polymorphisms that could reside far upstream of the initiation site). However, in view of the relatively small expression imbalance, we judged it to be unlikely that any functional polymorphism we might identify would have substantial effect on interindividual variability in PEPT1 intestinal activity. Therefore, we did not pursue the functional genetic variants responsible for the allelic expression imbalance.
Alternative splicing leads to the formation of PEPT1-RF that modulates transport activity of PEPT1 (Saito et al., 1997) . Alternative splicing occurs at exon 3 and yields a product that shares several exons with the wild-type PEPT1 (Urtti et al., 2001) . We determined the extent of PEPT1-RF mRNA formation in 32 intestinal samples, showing a variance of 2 -44% of total PEPT1 mRNA activity. Because the marker SNP we selected for the allelic expression imbalance assay resides in exon 17, not present in PEPT1-RF, we cannot determine whether variable splicing is mediated by cis-acting factors, or in trans. Our sequence analysis failed to reveal any sufficiently frequent polymorphisms in the relevant splice region, arguing against the presence of cis-acting factors. Moreover, we cannot determine whether PEPT1/PEPT-RF mRNA ratios are constant within the same individual or fluctuate with nutrition, age, disease, etc. Before these questions are addressed, in vitro studies need to be performed to determine whether PEPT1-RF has the potential to significantly affect PEPT1 transport at the levels found in the intestinal samples.
In conclusion, characterization of the non-synonymous SNPs reveals an absence of functional SNPs of sufficient frequency to exert significant impact on bioavailability of PEPT1
substrates. Similarly, any cis-acting factors affecting mRNA expression and processing are unlikely to have strong impact on intestinal PEPT1 transport. Possibly, genetic factors could introduce some systematic variability for drugs critically dependent on PEPT1 activity for intestinal absorption. However, other factors acting on PEPT1 transport activity are more likely to cause interindividual variability, recently studied with VAC in human subjects (Phan et al., 2003) .
Alternative splicing cannot as yet be ruled out as a clinically relevant variable. Overall, however, PEPT1 displays remarkable low genetic variability. This finding is important for drug therapy with peptoid drugs, and for exploiting PEPT1 in prodrug design for improved bioavailability. 
